World-Class Hematology Care in Shanghai
Shanghai is home to one of the world's most distinguished hematology centers — the Department of Hematology at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine — offering international patients access to the full spectrum of blood cancer diagnosis and treatment, from leukemia and lymphoma to multiple myeloma, bone marrow failure, and CAR-T cell therapy. Two of China's foremost hematologists lead this internationally recognized program: Dr. Zhao Weili (赵维莎), Director of Hematology at Ruijin Hospital and a world-leading expert in lymphoma, and Academician Chen Saijuan (陈赛娟), a globally recognized pioneer in leukemia genetics and precision hematology whose work on acute promyelocytic leukemia (APL) has saved hundreds of thousands of lives worldwide. Together, their department represents one of the world's premier centers for blood cancer research and treatment.
What Blood Conditions Are Treated?
Ruijin Hospital's Hematology Department offers comprehensive management of all major blood cancers and hematological conditions, including:
- Acute myeloid leukemia (AML) — including acute promyelocytic leukemia (APL), the world-leading ATRA + arsenic trioxide protocol
- Acute lymphoblastic leukemia (ALL) — including Ph+ ALL and T-ALL
- Chronic myeloid leukemia (CML) — TKI therapy (imatinib, dasatinib, ponatinib)
- Chronic lymphocytic leukemia (CLL) — BTK inhibitors (ibrutinib, zanubrutinib), venetoclax
- Diffuse large B-cell lymphoma (DLBCL) — R-CHOP, CAR-T cell therapy for relapsed/refractory disease
- Follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma
- Hodgkin lymphoma — ABVD, brentuximab vedotin, PD-1 inhibitors
- T-cell lymphomas — including PTCL, AITL, NK/T-cell lymphoma
- Multiple myeloma — proteasome inhibitors, IMiDs, anti-CD38 antibodies, autologous stem cell transplant
- Myelodysplastic syndrome (MDS) — azacitidine, lenalidomide, allogeneic stem cell transplant
- Aplastic anemia — immunosuppressive therapy and allogeneic stem cell transplant
- CAR-T cell therapy for relapsed/refractory B-cell lymphoma and ALL
- Allogeneic and autologous hematopoietic stem cell transplantation (HSCT)
Why International Patients Choose Ruijin for Hematology
International patients choose Ruijin Hospital's Hematology Department for its exceptional combination of world-class clinical expertise and cutting-edge research — a department that has not only treated thousands of blood cancer patients but has fundamentally changed how leukemia is treated globally. For patients with acute promyelocytic leukemia (APL), Ruijin Hospital is the birthplace of the ATRA + arsenic trioxide protocol — the most effective leukemia treatment ever developed — and remains the world's leading center for APL management. For patients with relapsed or refractory diffuse large B-cell lymphoma who need CAR-T cell therapy, Ruijin's CAR-T program offers access to approved and investigational CAR-T products with a team that has extensive experience managing CAR-T toxicities. For patients with multiple myeloma or MDS who need allogeneic stem cell transplantation, the department's transplant program offers comprehensive donor matching, conditioning regimen optimization, and post-transplant care.
How CMCS Arranges Your Appointment
CMCS manages every aspect of your hematology visit so you can focus on your health and treatment. Here's how we help:
- Initial Consultation: Contact CMCS and share your blood counts, bone marrow biopsy reports, molecular testing results, and treatment history.
- Case Review: Our team reviews your case and identifies the most appropriate hematologist within Ruijin's department for your specific blood condition.
- Appointment Booking: We coordinate directly with Ruijin Hospital to secure your consultation at a convenient time.
- Pre-Visit Preparation: We advise on which pathology materials, molecular test results, and imaging to bring or send in advance.
- On-the-Day Support: A CMCS coordinator accompanies you through registration, consultation, and any same-day blood tests or bone marrow assessments.
- Treatment Coordination: If treatment in Shanghai is recommended — including chemotherapy, CAR-T therapy, or stem cell transplant — CMCS helps coordinate hospital admission and ongoing care logistics.
What to Prepare Before Your Visit
To ensure the most productive hematology consultation, please prepare:
- Complete blood count (CBC) with differential — serial values over time
- Bone marrow biopsy and aspirate pathology report — including morphology, immunohistochemistry, flow cytometry
- Cytogenetics (karyotype) and FISH results
- Molecular testing: NPM1, FLT3-ITD, IDH1/2, TP53, BCR-ABL, JAK2, CALR (as relevant to your condition)
- NGS panel results (if available)
- PET-CT scan report (for lymphoma staging)
- Lymph node biopsy pathology with immunohistochemistry and molecular profiling (for lymphoma)
- Serum protein electrophoresis (SPEP), immunofixation, free light chains (for myeloma)
- Records of all prior hematological treatments and response assessments
- A full list of current medications
- Your passport and travel/health insurance documents
What to Expect on the Day
Ruijin Hospital's Hematology Department is equipped with state-of-the-art flow cytometry, molecular diagnostics, bone marrow biopsy facilities, a dedicated CAR-T cell therapy unit, and a comprehensive stem cell transplant program. Your consultation will involve a thorough review of your blood counts, bone marrow pathology, and molecular profile, followed by a clear discussion of treatment options — including standard chemotherapy, novel targeted agents, CAR-T therapy, or stem cell transplantation. CMCS will ensure all communication is clear and that you leave with a complete understanding of your blood condition and the recommended treatment plan.
Contact CMCS to Get Started
Ready to book your hematology consultation at Ruijin Hospital? Contact our team today:
CMCS is your trusted medical concierge partner in Shanghai — making world-class Chinese healthcare accessible to international patients.
0 条评论